Information Provided By: 
Fly News Breaks for February 12, 2019
GERN
Feb 12, 2019 | 18:58 EDT
BTIG analyst Thomas Shrader initiated Geron with a Buy rating and a price target of $4.00. The analyst says the stock has been "left for dead" even though the study of "Imetelstat - a telomerase inhibitor active in the treatment of highly transfusion-dependent MDS and r/r myelofibrosis" showed clear indications of efficacy. Shrader notes the company will take over the development of Imetelstat with pivotal trials starting this year and may attract "investor interest as corroborative pivotal readouts approach."
News For GERN From the Last 2 Days
There are no results for your query GERN
